• Vilon peptide and cardiovascular health research
Een gemene
X
Een gemene

Vilon 20mg (Bioregulator)

Categorieën:, ,

Contact om te bestellen
Mail ons nu om je bestelling te plaatsen met 1-op-1 ondersteuning. Beperkte voorraad! Wij accepteren Zelle, CashApp, Venmo, bankoverschrijving en crypto.
Bacteriostatisch water

Gratis (1) 30 ml bacteriostatisch water
met gekwalificeerde bestellingen over$ 500 USD. (sluit capsuleproducten, cosmetische peptiden, promotiecodes en verzending uit)

Vilon is een krachtige immunomodulator en anti-aging bioregulator-peptide met voldoende onderzoek om de voordelen ervan te ondersteunen. Er zijn ook een hoog bewijs dat Vilon het risico op de ontwikkeling en progressie van kanker kan helpen voorkomen/verminderen. Interessant is dat onderzoek heeft aangetoond dat Vilon betere anti-verouderingseffecten lijkt te bieden wanneer het vroeg in het leven wordt toegediend en bij consistente, lage doses. Deze bevindingen kunnen helpen de deur te openen voor beter anti-verouderingsonderzoek en wetenschappers helpen om beter te begrijpen hoe epigenetische regulatie een belangrijke rol speelt in de levensduur.
Productgebruik:Dit product is alleen bedoeld als een onderzoeks chemisch.Deze aanduiding maakt het gebruik van onderzoekschemicals strikt mogelijk voor alleen in vitro testen en laboratoriumexperimentatie. Alle productinformatie die op deze website beschikbaar is, is alleen voor educatieve doeleinden. Lichamelijke introductie van welke aard dan ook in mensen of dieren is ten strengste wettelijk verboden. Dit product mag alleen worden afgehandeld door erkende, gekwalificeerde professionals. Dit product is geen medicijn, voedsel of cosmetisch en is mogelijk niet verkeerd, misbruikt of misbruikt als medicijn, voedsel of cosmetisch.

Een gemene

Bij slechts twee aminozuren lang is Vilon het kortste peptide waarvan bekend is dat het biologische activiteit heeft. Onderzoek toont aan dat Vilon krachtige anti-verouderingseffecten heeft en dat het een krachtige regulator van de immuunfunctie is. Er is ook goed bewijs dat Vilon helpt om het vasculaire systeem te reguleren en hemostase bevordert. Van Vilon is aangetoond dat het de incidentie en groei van spontane tumoren vermindert, hoewel zijn rol als adjuvans bij de behandeling van kanker (in tegenstelling tot preventie) in twijfel is getrokken. Over het algemeen heeft Vilon verschillende fervent voorstanders, zoals Dr. Vladimir Anisimov, die het gevoel hebben dat het peptide een nuttig geroprotectief middel is.
Molecuul

Vilon en het immuunsysteem

Research out of Russia indicates that Vilon is a potent regulator of chromatin structure. One study found that Vilon: • induces unrolling of chromatin, • activates synthetic processes via reactivation of ribosomal genes in the unrolled chromatin, • releases repressed genes, and • does not cause decondensation of pericentromeric structural chromatin[1].nduces unrolling of chromatin, The net result of the changes that Vilon causes to DNA is reactivation of genes that are otherwise silenced. In general, chromatin is found in either the wound (heterochromatin) or unwound (euchromatin) states. Heterochromatin cannot be accessed by the apparatus that turns genes into proteins and thus functional components of the cell. Genes in these regions of DNA are simply unavailable for protein production. In general, chromatin helps to regulate which genes are available for transcription and is thus one way that different-cells can have different functions or that the same cells can have different functions over time. Unfortunately, chromatin condensation is also something that occurs as a result of aging and senescence and is at least one reason why our cells and tissues lose function as we get older. Similar to its activity in lymphocytes, Vilon has been shown to activate interluekin-2 signaling in cells of the spleen[3]. Interleukin-2 is important in coordinating the immune response to microbial infection and helps to prevent autoimmune reactions. By activating lymphocytes and splenocytes while boosting natural protection against autoimmune reactions, Vilon restores the immune system to a more active state and may even be useful in developing treatments for autoimmune diseases. Adding to its ability to prevent autoimmune reactions is the role of Vilon in the thymus. Research in thymus cultures shows that Vilon increases the proliferation of CD5 T-cells. CD5 is a marker of mature T-helper cells as well as cytotoxic CD8 T-cells. The former helps to regulate the immune system and prevent autoimmune reactions, while the latter is one of the most potent anti-microbial cells in the body[4]. Interestingly, Vilon appears to only reactivate immune functions via genes that have been silenced by changes in chromatin. It does not appear to activate genes that would naturally be silent in the cells it affects. In other words, Vilon does not turn lymphocytes into neurons by activating genes that would normally not be active in healthy lymphocytes. Instead, the peptide appears to boost activity in the immune system while simultaneously helping to prevent autoimmune reactions.

Vilon en kanker

As pointed out above, Vilon helps to reduce the incidence of cancer in mouse models, which is at least one way in which it prolongs average lifespan. Additional research shows that Vilon not only prevents tumors from forming, but inhibits their growth after they are present[5]. This suggests that Vilon may be both an effective chemotherapeutic in its own right, as well as a potential additive to existing cancer treatments. In the future, Vilon may be a standard addition to everything from chemotherapy to radiation treatment and surgery. At least one study, out of Russia, contradicts the claim that Vilon may be a useful adjuvant to chemotherapy. The works shows that the combination of Vilon and platinum-based chemotherapeutic agents is problematic rather than synergistic[6]. Unfortunately, this study used only one specific type of chemotherapy and was limited in scope, so the results cannot be generalized. It remains to be seen if Vilon is only effective against cancer on its own or if the peptide can be added to other treatment regimens to boost results.

Vilon en ouder worden

Research in mice shows that subcutaneous administration of Vilon increases physical activity and endurance while helping to reduce the risk of cancer. These two effects resulted in longer lifespan in the treated mice, suggesting that Vilon may be a legitimate anti-aging peptide[7]. This is especially encouraging given that it produced no adverse effects in the mice following long-term administration. Interestingly, the research shows that the earlier Vilon is administered, the greater its effects seem to be. In other words, giving Vilon to young mice enhances lifespan more than if Vilon is not administered until the mice are much older. This same effect was seen in early studies looking at crude thymic and pineal extracts given to mice to slow down aging[8]. The speculation is that Vilon and similar peptides, when administered late in life, can reverse senescence in existing cells but can obviously do nothing for cells that have already been eliminated through apoptosis. By administering Vilon 20mg early in life, cells get the greatest amount of protection and so turnover is slowed down. The result is that more cells stay healthy for longer periods of time, slowing the need to replace them and preserving limited stem cell lines. Vilon’s anti-aging effects seem to extend to GI function as well, where the peptide has been shown to improve the activity of certain enzymes in the Gi tracts of older mice. The peptide also appears to improve barrier function, thus reducing the incidence of leaky gut, enhancing disease resistance, and improving the overall health of the GI tract in older mice[9]. Research shows that Vilon thereby helps to improve glucose and glycine absorption in the small intestine of older rats[10]. These features of Vilon may help to maintain nutrient extraction with age, thereby improving overall well-being and perhaps enhancing longevity. Dr. Vladimir N. Anisimov, who has been researching aging and cancer development since the 1970s, points out that the thymus is one of two glands (the other being the pineal gland) that plays an important role in regulating aging. The healthier the thymus is, the healthier we are as individuals. Of course, Vilon is a thymic peptide and affects cells, like lymphocytes, that are produced in and mature in the thymus. Dr. Anisimov is a staunch advocate for using peptide bioregulators in the prevention of cancer[11]. He is a close colleague of Dr. Vladimir Khavinson.

Vilon in het hart en de nieren

The effect of Vilon on the vasculature has been less well studied, but there is some work to suggest that it may have a beneficial effect. Research in mice shows that Vilon changes the expression of more than 36 different genes within the heart. When combined with Epithalon, this number jumps to 144 genes[12]. These findings suggest that, at the very least, Vilon has the ability to alter gene expression patterns in the cardiovascular system, a fact that may improve hemodynamic function. In fact, research in kidneys, highly vascular organs, shows that Vilon decreases concentrations of transforming growth factor-beta(1) and thus the permeability of microvessels. The net result is improved hemostasis during kidney failure, suggesting that Vilon does, in fact, have a beneficial effect on the vascular system[13]. Furthermore, research in elderly patients with diabetes shows that Vilon can help to optimize coagulation by increasing levels of the natural anticoagulants antithrombin III and protein C while also stimulating fibrinolysis[14]. The result is fewer blood clots in a population prone to clotting and the serious consequences that follow. This further supports the idea that Vilon plays an important role in regulating the vascular system.

Vilon Samenvatting

Vilon is a potent immunomodulator and anti-aging peptide with ample research to back its benefit. There are also high levels of evidence that Vilon reduces the risk of cancer development and progression. Interestingly, Vilon appears to provide better anti-aging and anti-cancer effects when administered early in life and at chronic, low doses. These features may help open the door to better anti-aging research and help scientists to better understand how epigenetic regulation plays an important role in longevity. Vilon exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Vilon for sale at
Peptidegoeroesis alleen beperkt tot educatief en wetenschappelijk onderzoek, niet voor menselijke consumptie. Koop alleen Vilon als u een erkende onderzoeker bent.

Artikelauteur

De bovenstaande literatuur werd onderzocht, bewerkt en georganiseerd door Dr. E. Logan, M.D. Dr. E. Logan behaalde een doctoraat vanCase Western Reserve University School of Medicineen een B.S. in moleculaire biologie.

Wetenschappelijke tijdschrift Auteur

Vladimir Khavinsonis een professor, president van de Europese regio van de International Association of Gerontology and Geriatrics; Lid van deRussische en Oekraïense academies van medische wetenschappen; Hoofd gerontoloog van de gezondheidscommissie van de regering van Saint Petersburg, Rusland; Directeur van het Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president van Gerontological Society of theRussische Academie van Wetenschappen; Hoofd van de voorzitter van Gerontology and Geriatrics van de Thenorth-Western State Medical University, St-Petersburg; Kolonel van de medische dienst (USSR, Rusland), gepensioneerd. Vladimir Khavinson staat bekend om de ontdekking, experimentele en klinische studies van nieuwe klassen vanPeptideBioregulatoren en voor de ontwikkeling van bioregulerende peptidetherapie. Hij is bezig met het bestuderen van de rol van peptiden bij de regulatie van de verouderingsmechanismen. Zijn hoofdveld van acties is ontwerp, pre-klinische en klinische studies van nieuw peptidegeroprotectoren. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications.His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002)and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005).Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries. Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Livagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between
Peptidegoeroesen deze dokter. Het doel van het citeren van de arts is om de uitputtende onderzoeks- en ontwikkelingsinspanningen van de wetenschappers die dit peptide bestuderen te erkennen, te erkennen en te crediteren. Prof. Vladimir Khavinson is vermeld in [1] [3] [4] [5] [7] [8] [9] [10] [11] en [12] onder de citaten waarnaar wordt verwezen.

Vermeld citaten

    [1] T. Lezhavaet al., “Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people,”Biogerontology, vol. 5, no. 2, pp. 73–79, 2004, doi: 10.1023/B:BGEN.0000025070.90330.7f. [2] T. Lezhava, J. Monaselidze, T. Kadotani, N. Dvalishvili, and T. Buadze, “Anti-aging peptide bioregulators induce reactivation of chromatin,”Georgian Med. News, no. 133, pp. 111–115, Apr. 2006. [3] T. B. Kazakovaet al., “In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes,”Bull. Exp. Biol. Med., vol. 133, no. 6, pp. 614–616, Jun. 2002, doi: 10.1023/a:1020210615148. [4] N. N. Sevostianovaet al., “Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells,”Bull. Exp. Biol. Med., vol. 154, no. 4, pp. 562–565, Feb. 2013, doi: 10.1007/s10517-013-2000-0. [5] V. K. Khavinson and V. N. Anisimov, “A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice,”Dokl. Biol. Sci. Proc. Acad. Sci. USSR Biol. Sci. Sect., vol. 372, pp. 261–263, Jun. 2000. [6] O. P. Barykina, V. V. Iuzhakov, N. I. Chalisova, I. M. Kvetnoĭ, and S. S. Konovalov, “[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age],”Adv. Gerontol. Uspekhi Gerontol., vol. 12, pp. 128–131, 2003. [7] V. K. Khavinsonet al., “Effect of vilon on biological age and lifespan in mice,”Bull. Exp. Biol. Med., vol. 130, no. 7, pp. 687–690, Jul. 2000, doi: 10.1007/BF02682106. [8] V. N. Anisimov, A. S. Loktionov, V. K. Khavinson, and V. G. Morozov, “Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female mice of different age,”Mech. Ageing Dev., vol. 49, no. 3, pp. 245–257, Sep. 1989, doi: 10.1016/0047-6374(89)90075-4. [9] V. K. Khavinson, N. M. Timofeeva, V. V. Malinin, L. A. Gordova, and A. A. Nikitina, “Effect of vilon and epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats,”Bull. Exp. Biol. Med., vol. 134, no. 6, Art. no. 6, Dec. 2002. [10 ]V. K. Khavinson, V. V. Egorova, N. M. Timofeeva, V. V. Malinin, L. A. Gordova, and L. V. Gromova, “Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats,”Bull. Exp. Biol. Med., vol. 133, no. 5, pp. 494–496, May 2002, doi: 10.1023/a:1019878224754. [11] V. N. Anisimov and V. K. Khavinson, “[The use of peptide bioregulators for cancer prevention: results of 35 years of research experience and perspectives],”Vopr. Onkol., vol. 55, no. 3, pp. 291–304, 2009. [12] S. V. Anisimov, K. R. Bokheler, V. K. Khavinson, and V. N. Anisimov, “Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology,”Bull. Exp. Biol. Med., vol. 133, no. 3, pp. 293–299, Mar. 2002, doi: 10.1023/a:1015859322630. [13] N. A. Gavrisheva, V. V. Malinin, T. P. Ses, K. L. Kozlov, A. V. Panchenko, and A. Y. Titkov, “Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure,”Bull. Exp. Biol. Med., vol. 139, no. 1, pp. 24–26, Jan. 2005, doi: 10.1007/s10517-005-0202-9. [14] B. I. Kuznik, N. V. Isakova, N. N. Kliuchereva, N. V. Maleeva, and I. S. Pinelis, “[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus],”Adv. Gerontol. Uspekhi Gerontol., vol. 20, no. 2, pp. 106–115, 2007.
Alle artikelen en productinformatie op deze website zijn alleen voor informatieve en educatieve doeleinden.De producten die op deze website worden aangeboden, zijn alleen ingericht voor in-vitro-studies. In-vitro-onderzoeken (Latijn: in glas) worden buiten het lichaam uitgevoerd. Deze producten zijn geen medicijnen of medicijnen en zijn niet goedgekeurd door de FDA om een ​​medische aandoening, kwaal of ziekte te voorkomen, te behandelen of te genezen. Lichamelijke introductie van welke aard dan ook in mensen of dieren is ten strengste wettelijk verboden.

Aanvraag aanvragen

Over ons

Peptidegurus is een toonaangevende leverancier van Amerikaanse onderzoekspeptiden en biedt producten van topkwaliteit tegen concurrerende prijzen. Met een focus op excellentie en klantenservice, zorgen ze voor een veilig en handig bestelproces met wereldwijde verzending.

Producten

Vraag een citaat aan

  • Peptidegoeroes
    • info@peptidegurus.com
  • Glendale, het is, VS

    • CONTACT

    Aanvraag aanvragen